https://www.selleckchem.com/pr....oducts/relacorilant.
Approximately 15-30% of patients with lung cancer harbor mutations in the EGFR gene. Major EGFR mutations (90% of EGFR-mutated lung cancer) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). Many uncommon EGFR mutations have been identified, but little is known regarding their characteristics, activation, and sensitivity to various EGFR-TKIs, including allosteric inhibitors. We encountered a case harboring an EGFR-L747P mutation, originally misdiagnosed with EGFR-del19 mutation using a routine diagnostic EGFR mutat
Gefällt mir
Kommentar
Teilen
